Understanding the regulatory pathway for bringing dietary supplements to market in the United States begins with a fundamental distinction regarding the FDA food supplements approval process. Unlike pharmaceutical drugs, which undergo rigorous pre-market review and must prove safety and efficacy before sale, dietary supplements are regulated as a category of food. This means that while the FDA monitors the safety and labeling of these products, manufacturers are not required to submit their formulations for formal approval before distributing them to consumers.
The Legal Framework: DSHEA of 1994
The foundation of the current system is the Dietary Supplement Health and Education Act (DSHEA) of 1994. This landmark legislation shifted the responsibility for ensuring the safety of dietary supplements from the government to the manufacturers. Prior to DSHEA, supplements were subject to the same strict approval process as drugs. The new framework established that a product is considered safe until proven otherwise, placing the onus on the FDA to identify and remove unsafe products from the market after they are already being sold.
Notifying the FDA: A Manufacturer’s Responsibility
Although there is no pre-market approval, manufacturers and distributors are required to register their facility with the FDA and submit a notification regarding the dietary supplement they are marketing. This New Dietary Ingredient (NDI) notification is a critical step, particularly for ingredients that were not sold in the United States in significant amounts before October 15, 1994. This notification alerts the agency to the product’s existence and provides information about the ingredient, its source, and the intended use, allowing the FDA to evaluate any potential safety concerns.
Post-Market Surveillance and Adverse Event Reporting
The FDA’s oversight is largely reactive, relying on a system of post-market surveillance to protect public health. Manufacturers are mandated to report any serious adverse events associated with their products to the FDA. This includes reports of death, hospitalization, disability, or other significant medical events. The agency actively monitors these reports and can take action, such as issuing warning letters or initiating product recalls, if it determines that a product is unsafe or if its labeling is false or misleading.
Labeling and Claims: Navigating the Regulations
A crucial aspect of compliance is the labeling and structure/function claims. Supplement labels cannot claim to diagnose, treat, cure, mitigate, or prevent any disease, as this would classify the product as an unapproved drug. Instead, they are allowed to make structure/function claims, which describe how a nutrient or ingredient affects the body's normal structure or function. For example, stating that a supplement "supports immune function" is permissible, but claiming it "prevents the flu" is not. Furthermore, labels must include a disclaimer stating that the product has not been evaluated by the FDA and that the product is not intended to "diagnose, treat, cure or prevent any disease."
